Pfizer pneumococcal vaccine for children meets main goals in late-stage trial (NYSE:PFE)

Retrieved on: 2022-08-12 11:17:32

Tags for this article:

Vaccines

Pneumonia

Medical specialties

Medicine

Bacteria

Pneumococcal conjugate vaccine

Pneumococcal vaccine

Streptococcus pneumoniae

Pfizer

Vaccine

Conjugate vaccine

Pneumococcal polysaccharide vaccine

Getty Images

Click the tags to see associated articles and topics

Pfizer pneumococcal vaccine for children meets main goals in late-stage trial (NYSE:PFE). View article details on hiswai:

Excerpt

Pfizer (PFE) announced Friday that the company's 20-valent pneumococcal conjugate vaccine candidate named 20vPnC met the co-primary endpoints in a ...

Article found on: seekingalpha.com

View Original Article